Abstract
Cutaneous adverse events to dupilumab can be varied; this necessitates keeping a broad differential diagnosis to identify seemingly paradoxical reactions. It may be possible to treat the adverse event concurrently without stopping dupilumab.
Author supplied keywords
Cite
CITATION STYLE
APA
Al-Janabi, A., & Marsland, A. M. (2020). Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports. Clinical Case Reports, 8(8), 1458–1460. https://doi.org/10.1002/ccr3.2871
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free